Literature DB >> 35202907

Clinical significance of Vimentin Antisense RNA 1 and its correlation with other epithelial to mesenchymal transition markers in oral cancers.

Esra Bozgeyik1, Bilal Ege2, Mehtap Koparal3, Onur Ceylan4.   

Abstract

Oral squamous cell carcinoma (OSCC) is the most common form of malignant tumor in the head and neck region worldwide. Hence, the identification of biological signatures with high diagnostic and therapeutic potential for OSCC will be of great clinical importance. Epithelial to mesenchymal transition (EMT) is a key driver of malignant transformation of human tumors including OSCC. Loss of epithelial properties and gain of mesenchymal cell properties is one of the most important hallmarks of malignant tumors. Although much has been reported on the protein components of the EMT process, studies on the non-protein coding components are quite limited. Consequently, here we sought to explore biological significance of VIM antisense RNA 1 (VIM-AS1) in OSCC. A total of 36 patients diagnosed with oral cancer were recruited for the study. Formalin-fixed paraffin embedded (FFPE) tissue samples of patients were obtained from pathology archive. For the gene expression analysis, quantitative RT-PCR was used. We also analyzed the expression levels of E-cadherin and Vimentin. Notably, it was found that the expression levels of VIM-AS1 and Vimentin were significantly elevated, while the expression of E-cadherin was downregulated in OSCC. Deregulation of VIM-AS1 was associated with the clinicopathological features of OSCC patients. ROC analysis also showed that VIM-AS1 is an independent diagnostic biomarker for OSCC. Consequently, our findings suggest a chief role for VIM-AS1 in oral cancers.
Copyright © 2022 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  E-cadherin; EMTOral squamous cell carcinoma; Epithelial to mesenchymal transition; OSCC; VIM -AS1; Vimentin

Mesh:

Substances:

Year:  2022        PMID: 35202907     DOI: 10.1016/j.prp.2022.153807

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  2 in total

1.  The Combination of Zerumbone with 5-Fluorouracil for Sensitizing Colorectal Cancer-Associated Fibroblasts to Treatment.

Authors:  Sima Nobari; Rezvan Najafi; Ali Mahdavinezhad; Akram Jalali; Razieh Amini
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-11       Impact factor: 2.650

2.  Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments.

Authors:  Jason Thomas Duskey; Arianna Rinaldi; Ilaria Ottonelli; Riccardo Caraffi; Chiara Alessia De Benedictis; Ann Katrin Sauer; Giovanni Tosi; Maria Angela Vandelli; Barbara Ruozi; Andreas Martin Grabrucker
Journal:  Pharmaceutics       Date:  2022-07-12       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.